• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Efficacy and safety of necitumumab continuation therapy in the Phase III SQUIRE study of patients with stage IV squamous non-small-cell lung cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Ciuleanu, T
    Socinski, M
    Obasaju, C
    Luft, A
    Szczesna, A
    Szafrański, W
    Ramlau, R
    Bálint, B
    Molinier, O
    Depenbrock, H
    Nanda, S
    Paz-Ares, L
    Thatcher, Nick
    Show allShow less
    Affiliation
    Medical Oncology, Institute of Oncology Ion Chiricuta and UMF Iuliu Hatieganu, Cluj Napoca, Romania
    Issue Date
    2017-10-13
    
    Metadata
    Show full item record
    Abstract
    In a retrospective analysis of the SQUamous NSCLC treatment with the Inhibitor of EGF REceptor (SQUIRE) study, we investigated the efficacy and safety of single-agent necitumumab continuation therapy in patients with stage IV squamous non-small-cell lung cancer and in a subpopulation of patients with epidermal growth factor receptor (EGFR)-expressing tumors.
    Citation
    Efficacy and safety of necitumumab continuation therapy in the Phase III SQUIRE study of patients with stage IV squamous non-small-cell lung cancer 2017, Clin Lung Cancer
    Journal
    Clinical Lung Cancer
    URI
    http://hdl.handle.net/10541/620740
    DOI
    10.1016/j.cllc.2017.10.004
    PubMed ID
    29158123
    Type
    Article
    Language
    en
    ISSN
    1938-0690
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.cllc.2017.10.004
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.
    • Authors: Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR
    • Issue date: 2016 Aug
    • Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
    • Authors: Reck M, Thomas M, Kropf-Sanchen C, Mezger J, Socinski MA, Depenbrock H, Soldatenkova V, Brown J, Krause T, Thatcher N
    • Issue date: 2016
    • Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    • Authors: Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA, SQUIRE Investigators
    • Issue date: 2015 Jul
    • Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
    • Authors: Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK, Soldatenkova V, Depenbrock H, Puri T, Orlando M
    • Issue date: 2017 Oct
    • The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
    • Authors: Reck M, Socinski MA, Luft A, Szczęsna A, Dediu M, Ramlau R, Losonczy G, Molinier O, Schumann C, Gralla RJ, Bonomi P, Brown J, Soldatenkova V, Chouaki N, Obasaju C, Peterson P, Thatcher N
    • Issue date: 2016 Jun
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.